Apollomics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Apollomics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 3/3Sales grew in 1 of the last 3 years; profit grew in 3 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-49.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 73% of Healthcare companies in United States.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Lower than 59% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Apollomics, Inc. made a loss over the last year. Apollomics, Inc. owes $1.47 for every $1 it owns. Apollomics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossApollomics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-20.12Apollomics, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$64 MThe total market value of all of Apollomics, Inc.'s shares at today's price (share price × number of shares), smaller than 71% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeApollomics, Inc.'s net worth is negative ($3 M below zero, balance sheet 31 Dec 2025): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-1305.4%Apollomics, Inc. lost 1305.4% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
Owes vs Owns
1.47×Apollomics, Inc. owes $1.47 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneApollomics, Inc. does not currently pay a dividend.
Profit growth
LossApollomics, Inc. made a loss in each of the last two years.
Profit margin
-128.7%Apollomics, Inc. lost $129 for every $100 of revenue.
Interest cover
Not coveredApollomics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashApollomics, Inc. held $3 M more cash than debt (net cash) at Dec 2025.
Questions
What is Apollomics, Inc.'s return on equity?
Apollomics, Inc. lost 1305.4% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
How much does Apollomics, Inc. owe compared with what it owns?
Apollomics, Inc. owes $1.47 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does Apollomics, Inc. pay a dividend?
No. Apollomics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.